We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Swiss Helvetia Fund Inc | NYSE:SWZ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.02 | -0.26% | 7.56 | 7.582 | 7.50 | 7.58 | 6,300 | 18:02:22 |
Net asset value returns
|
1 year
|
5 years
|
10 years
|
The Swiss Helvetia Fund, Inc.
|
16.92%
|
9.52%
|
6.09%
|
Market price returns
|
|||
The Swiss Helvetia Fund, Inc.
|
15.48%
|
9.76%
|
5.73%
|
Index returns
|
|||
Swiss Performance Index
|
16.54%
|
11.70%
|
6.99%
|
Share price as of 12/31/2023
|
|||
Net asset value
|
|
||
Market price
|
|
Schedule of Investments by Industry |
December 31, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — 97.78%
|
|||||||||||
Advertising — 1.15%
|
|||||||||||
21,000
|
DKSH Holding AG
|
$
|
1,457,138
|
1.15
|
%
|
||||||
An international
|
|||||||||||
marketing and services
|
|||||||||||
group. The company offers
|
|||||||||||
a comprehensive package
|
|||||||||||
of services that includes
|
|||||||||||
organizing and running
|
|||||||||||
the entire value chain
|
|||||||||||
for any product.
|
|||||||||||
(Cost $1,461,589)
|
|||||||||||
1,457,138
|
1.15
|
%
|
|||||||||
Banks — 3.03%
|
|||||||||||
425
|
St Galler Kantonalbank AG
|
248,188
|
0.19
|
%
|
|||||||
Offers retail and
|
|||||||||||
commercial banking
|
|||||||||||
as well as private and
|
|||||||||||
institutional banking.
|
|||||||||||
Also provides asset
|
|||||||||||
management and financial
|
|||||||||||
planning services.
|
|||||||||||
(Cost $200,119)
|
|||||||||||
116,000
|
UBS Group AG
|
3,597,220
|
2.84
|
%
|
|||||||
Provides retail banking,
|
|||||||||||
corporate and institutional
|
|||||||||||
banking, wealth
|
|||||||||||
management, asset
|
|||||||||||
management and
|
|||||||||||
investment banking.
|
|||||||||||
(Cost $1,582,000)
|
|||||||||||
3,845,408
|
3.03
|
%
|
|||||||||
Biotechnology — 2.28%
|
|||||||||||
10,801
|
Bachem Holding AG
|
|
834,153
|
0.66
|
%
|
||||||
Specializes in the
|
|||||||||||
development and
|
|||||||||||
manufacture of peptides
|
|||||||||||
and oligonucleotides.
|
|||||||||||
The company provides
|
|||||||||||
products for research,
|
|||||||||||
clinical development and
|
|||||||||||
commercial application to
|
|||||||||||
pharmaceutical and
|
|||||||||||
biotechnology companies.
|
|||||||||||
(Cost $827,767)
|
|||||||||||
41,308
|
Idorsia Ltd.1
|
103,755
|
0.08
|
%
|
|||||||
Researches, develops,
|
|||||||||||
and manufactures
|
|||||||||||
pharmaceutical, biological,
|
|||||||||||
and diagnostic products.
|
|||||||||||
(Cost $1,141,327)
|
|||||||||||
4,650
|
Lonza Group AG
|
1,954,143
|
1.54
|
%
|
|||||||
Produces organic fine
|
|||||||||||
chemicals, biocides, active
|
|||||||||||
ingredients, and
|
|||||||||||
biotechnology products.
|
|||||||||||
(Cost $2,620,486)
|
|||||||||||
2,892,051
|
2.28
|
%
|
|||||||||
Building Materials — 2.96%
|
|||||||||||
820
|
Forbo Holding AG
|
1,026,888
|
0.81
|
%
|
|||||||
Produces floor coverings,
|
|||||||||||
adhesives and belts for
|
|||||||||||
conveying and
|
|||||||||||
power transmission.
|
|||||||||||
(Cost $1,292,481)
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Building Materials — (continued)
|
|||||||||||
8,400
|
Sika AG
|
$
|
2,731,634
|
2.15
|
%
|
||||||
Manufactures construction
|
|||||||||||
materials, producing
|
|||||||||||
concrete and mixtures,
|
|||||||||||
mortar, sealants and
|
|||||||||||
adhesives, tooling resins,
|
|||||||||||
anti-static industrial
|
|||||||||||
flooring, and acoustic
|
|||||||||||
materials. The company
|
|||||||||||
serves customers worldwide.
|
|||||||||||
(Cost $1,566,770)
|
|||||||||||
3,758,522
|
2.96
|
%
|
|||||||||
Chemicals — 1.34%
|
|||||||||||
410
|
Givaudan SA
|
1,697,190
|
1.34
|
%
|
|||||||
Manufactures and markets
|
|||||||||||
fragrances and flavors
|
|||||||||||
from natural and synthetic
|
|||||||||||
ingredients. The Company
|
|||||||||||
sells its products to
|
|||||||||||
manufactures of perfumes,
|
|||||||||||
beverages, prepared foods,
|
|||||||||||
and consumer goods.
|
|||||||||||
(Cost $1,239,873)
|
|||||||||||
1,697,190
|
1.34
|
%
|
|||||||||
Computers — 1.68%
|
|||||||||||
18,000
|
Logitech International SA
|
1,705,792
|
1.34
|
%
|
|||||||
Engages in the
|
|||||||||||
development and
|
|||||||||||
marketing of hardware and
|
|||||||||||
software products that
|
|||||||||||
enable or enhance digital
|
|||||||||||
navigation, music and video
|
|||||||||||
entertainment, gaming,
|
|||||||||||
social networking and audio
|
|||||||||||
and video communication.
|
|||||||||||
(Cost $244,048)
|
|||||||||||
22,000
|
SoftwareONE Holding AG
|
|
428,682
|
0.34
|
%
|
||||||
Provides IT services. The
|
|||||||||||
Company offers cloud
|
|||||||||||
computing, portfolio
|
|||||||||||
management, procurement,
|
|||||||||||
unified communication,
|
|||||||||||
and other related solutions.
|
|||||||||||
(Cost $400,813)
|
|||||||||||
2,134,474
|
1.68
|
%
|
|||||||||
Diversified Financial Services — 3.27%
|
|||||||||||
27,000
|
Julius Baer Group Ltd.
|
1,512,565
|
1.19
|
%
|
|||||||
Provides private banking
|
|||||||||||
services. The company
|
|||||||||||
advises on wealth
|
|||||||||||
management, financial
|
|||||||||||
planning and investments;
|
|||||||||||
offers mortgage and other
|
|||||||||||
lending, foreign exchange,
|
|||||||||||
securities trading, custody
|
|||||||||||
and execution services.
|
|||||||||||
(Cost $1,314,961)
|
|||||||||||
6,000
|
Swissquote Group
|
||||||||||
Holding SA
|
1,458,563
|
1.15
|
%
|
||||||||
Through its subsidiaries,
|
|||||||||||
offers online financial
|
|||||||||||
services. The company
|
|||||||||||
operates an online trading
|
|||||||||||
system which offers
|
|||||||||||
customers real-time
|
|||||||||||
securities quotes on the
|
|||||||||||
Swiss Stock Exchange.
|
|||||||||||
(Cost $581,470)
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Diversified Financial Services — (continued)
|
|||||||||||
10,030
|
VZ Holding AG
|
$
|
1,170,256
|
0.93
|
%
|
||||||
Provides independent
|
|||||||||||
financial advice to private
|
|||||||||||
individuals and companies.
|
|||||||||||
The company consults on
|
|||||||||||
investment, tax and
|
|||||||||||
inheritance planning and
|
|||||||||||
provides advice regarding
|
|||||||||||
insurance products
|
|||||||||||
and coverage.
|
|||||||||||
(Cost $327,269)
|
|||||||||||
4,141,384
|
3.27
|
%
|
|||||||||
Electric — 1.54%
|
|||||||||||
11,000
|
BKW AG
|
1,953,900
|
1.54
|
%
|
|||||||
Provides energy supply
|
|||||||||||
services. The company
|
|||||||||||
focuses on the production,
|
|||||||||||
transportation, trading and
|
|||||||||||
sale of energy. In addition
|
|||||||||||
to energy supply, the
|
|||||||||||
company also develops,
|
|||||||||||
implements and operates
|
|||||||||||
energy solutions for
|
|||||||||||
its clients.
|
|||||||||||
(Cost $737,667)
|
|||||||||||
1,953,900
|
1.54
|
%
|
|||||||||
Electronic Components & Equipment — 2.73%
|
|||||||||||
35,500
|
ABB Ltd.
|
1,573,278
|
1.24
|
%
|
|||||||
Provides power and
|
|||||||||||
automation technologies.
|
|||||||||||
The company operates
|
|||||||||||
under segments that
|
|||||||||||
include power products,
|
|||||||||||
power systems, automation
|
|||||||||||
products, process
|
|||||||||||
automation, and robotics.
|
|||||||||||
(Cost $716,888)
|
|||||||||||
2,000
|
Comet Holding AG
|
|
630,191
|
0.50
|
%
|
||||||
Develops, produces, and
|
|||||||||||
distributes components
|
|||||||||||
and systems for x-ray tubes,
|
|||||||||||
vacuum condensers, and
|
|||||||||||
radio frequency, as well as
|
|||||||||||
other medical products.
|
|||||||||||
(Cost $402,700)
|
|||||||||||
100,000
|
R&S Group Holding AG1
|
1,259,431
|
0.99
|
%
|
|||||||
Manufactures small and
|
|||||||||||
medium power and
|
|||||||||||
distribution transformers
|
|||||||||||
and other components in
|
|||||||||||
the utility, infrastructure,
|
|||||||||||
and industrial sectors.
|
|||||||||||
(Cost $1,137,204)
|
|||||||||||
3,462,900
|
2.73
|
%
|
|||||||||
Food — 20.70%
|
|||||||||||
1,234,586
|
Aryzta AG1
|
2,276,573
|
1.79
|
%
|
|||||||
Produces and retails
|
|||||||||||
specialty bakery products.
|
|||||||||||
The Company produces
|
|||||||||||
French breads, pastries,
|
|||||||||||
continental breads,
|
|||||||||||
confections, artisan breads,
|
|||||||||||
homestyle lunches,
|
|||||||||||
viennoiserie, patisserie,
|
|||||||||||
cookies, pizza, appetizers,
|
|||||||||||
and sweet baked goods.
|
|||||||||||
(Cost $1,266,401)
|
|||||||||||
900
|
Barry Callebaut AG
|
1,517,376
|
1.20
|
%
|
|||||||
Manufactures cocoa and
|
|||||||||||
chocolate products. The
|
|||||||||||
Company markets to
|
|||||||||||
industrial food
|
|||||||||||
manufacturers, chocolatiers,
|
|||||||||||
pastry chefs, bakers, and
|
|||||||||||
retailers globally.
|
|||||||||||
(Cost $1,669,891)
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Food — (continued)
|
|||||||||||
193,837
|
Nestle SA
|
$
|
22,457,133
|
17.71
|
%
|
||||||
One of the world’s largest
|
|||||||||||
food and beverage
|
|||||||||||
processing companies.
|
|||||||||||
(Cost $12,557,687)
|
|||||||||||
26,251,082
|
20.70
|
%
|
|||||||||
Health Care — 2.34%
|
|||||||||||
70,000
|
Sandoz Group AG1
|
2,250,579
|
1.77
|
%
|
|||||||
Manufactures and
|
|||||||||||
distributes generic and
|
|||||||||||
biosimilar medicines for the
|
|||||||||||
treatment of patients with
|
|||||||||||
diseases such as cancer,
|
|||||||||||
diabetes, and arthritis.
|
|||||||||||
(Cost $1,574,032)
|
|||||||||||
2,000
|
Ypsomed Holding AG
|
720,014
|
0.57
|
%
|
|||||||
Develops and manufactures
|
|||||||||||
custom-made injection
|
|||||||||||
systems for pharmaceutical
|
|||||||||||
and bio-technology
|
|||||||||||
companies.
|
|||||||||||
(Cost $583,146)
|
|||||||||||
2,970,593
|
2.34
|
%
|
|||||||||
Healthcare-Products — 7.30%
|
|||||||||||
34,000
|
Alcon, Inc.
|
2,651,648
|
2.09
|
%
|
|||||||
Manufactures eye care
|
|||||||||||
products. The company
|
|||||||||||
produces and markets
|
|||||||||||
vitreoretinal and cataract
|
|||||||||||
surgery, contact lenses,
|
|||||||||||
and refractive
|
|||||||||||
technology products.
|
|||||||||||
(Cost $2,296,818)
|
|||||||||||
125,416
|
Eyesense AG, Series A1,2,3
|
|
1,490
|
0.00
|
%
|
||||||
A spin-out from Ciba Vision
|
|||||||||||
AG. Develops novel
|
|||||||||||
ophthalmic self- diagnostic
|
|||||||||||
systems for glucose
|
|||||||||||
monitoring of diabetes
|
|||||||||||
patients.
|
|||||||||||
(Cost $3,007,048)
|
|||||||||||
8,500
|
Medacta Group SA
|
1,268,461
|
1.00
|
%
|
|||||||
Produces and distributes
|
|||||||||||
medical devices. The
|
|||||||||||
company develops,
|
|||||||||||
manufactures, and
|
|||||||||||
distributes orthopedic
|
|||||||||||
and neurosurgical
|
|||||||||||
medical devices.
|
|||||||||||
(Cost $940,840)
|
|||||||||||
6,848
|
SKAN Group AG
|
657,421
|
0.52
|
%
|
|||||||
Provides health care
|
|||||||||||
supplies. The Company
|
|||||||||||
offers isolators,
|
|||||||||||
cleanroom devices, and
|
|||||||||||
decontamination processes
|
|||||||||||
for the aseptic production
|
|||||||||||
of the biopharmaceutical
|
|||||||||||
products.
|
|||||||||||
(Cost $530,142)
|
|||||||||||
3,000
|
Sonova Holding AG
|
978,079
|
0.77
|
%
|
|||||||
Designs and produces
|
|||||||||||
wireless analog and digital
|
|||||||||||
in-the-ear and behind-the-ear
|
|||||||||||
hearing aids and
|
|||||||||||
miniaturized voice
|
|||||||||||
communications systems.
|
|||||||||||
(Cost $457,261)
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Healthcare-Products — (continued)
|
|||||||||||
221,085
|
Spineart SA1,2,3
|
$
|
1,339,670
|
1.06
|
%
|
||||||
Designs and markets an
|
|||||||||||
innovative full range of
|
|||||||||||
spine products, including
|
|||||||||||
fusion and motion
|
|||||||||||
preservation devices,
|
|||||||||||
focusing on easy to implant
|
|||||||||||
high-end products to
|
|||||||||||
simplify the surgical act.
|
|||||||||||
(Cost $1,554,486)
|
|||||||||||
5,800
|
Tecan Group AG
|
2,366,447
|
1.86
|
%
|
|||||||
Manufactures and
|
|||||||||||
distributes laboratory
|
|||||||||||
automation components
|
|||||||||||
and systems. The products
|
|||||||||||
are mainly used by research
|
|||||||||||
and diagnostic laboratories.
|
|||||||||||
(Cost $815,502)
|
|||||||||||
9,263,216
|
7.30
|
%
|
|||||||||
Healthcare-Services — 0.77%
|
|||||||||||
11,300
|
Galenica AG
|
976,742
|
0.77
|
%
|
|||||||
Retails pharmaceutical
|
|||||||||||
products, and services
|
|||||||||||
customers in Switzerland.
|
|||||||||||
The Company offers health,
|
|||||||||||
beauty, and related
|
|||||||||||
products and services.
|
|||||||||||
(Cost $902,693)
|
|||||||||||
976,742
|
0.77
|
%
|
|||||||||
Industrials — 1.38%
|
|||||||||||
1,252
|
Belimo Holding AG1
|
689,928
|
0.55
|
%
|
|||||||
Manufactures heating,
|
|||||||||||
ventilation and air
|
|||||||||||
conditioning equipment.
|
|||||||||||
(Cost $144,479)
|
|||||||||||
234,000
|
OC Oerlikon Corp. AG
|
|
1,055,384
|
0.83
|
%
|
||||||
Manufactures industrial
|
|||||||||||
equipment. The Company
|
|||||||||||
produces protective
|
|||||||||||
coatings for precision
|
|||||||||||
tools and components,
|
|||||||||||
equipment for textile
|
|||||||||||
production, and propulsion
|
|||||||||||
technology drive systems.
|
|||||||||||
(Cost $2,574,223)
|
|||||||||||
1,745,312
|
1.38
|
%
|
|||||||||
Insurance — 8.32%
|
|||||||||||
12,000
|
Baloise Holding AG
|
1,879,166
|
1.48
|
%
|
|||||||
Offers group and individual
|
|||||||||||
life, health, accident,
|
|||||||||||
liability property, and
|
|||||||||||
transportation insurance
|
|||||||||||
to customers in Europe.
|
|||||||||||
The Company also offers
|
|||||||||||
private banking and asset
|
|||||||||||
management services.
|
|||||||||||
(Cost $1,807,178)
|
|||||||||||
6,700
|
Helvetia Holding AG
|
922,628
|
0.73
|
%
|
|||||||
Provides a broad range of
|
|||||||||||
life, casualty, liability,
|
|||||||||||
accident and transportation
|
|||||||||||
insurance in Switzerland
|
|||||||||||
and in other European
|
|||||||||||
countries. The Company
|
|||||||||||
insures individuals, property
|
|||||||||||
such as vehicles and
|
|||||||||||
buildings, and consumer
|
|||||||||||
goods and personal
|
|||||||||||
belongings.
|
|||||||||||
(Cost $579,944)
|
|||||||||||
3,263
|
Swiss Life Holding AG
|
2,264,115
|
1.79
|
%
|
|||||||
Provides life insurance
|
|||||||||||
and institutional
|
|||||||||||
investment management.
|
|||||||||||
(Cost $785,435)
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Insurance — (continued)
|
|||||||||||
10,500
|
Zurich Insurance
|
||||||||||
Group AG
|
$
|
5,484,227
|
4.32
|
%
|
|||||||
Provides insurance-based
|
|||||||||||
financial services. The
|
|||||||||||
company offers general
|
|||||||||||
and life insurance products
|
|||||||||||
and services for individuals,
|
|||||||||||
small businesses, commercial
|
|||||||||||
enterprises, mid-sized and
|
|||||||||||
large corporations, and
|
|||||||||||
multinational companies.
|
|||||||||||
(Cost $3,383,755)
|
|||||||||||
10,550,136
|
8.32
|
%
|
|||||||||
Machinery-Diversified — 0.76%
|
|||||||||||
31,000
|
Accelleron Industries AG
|
967,219
|
0.76
|
%
|
|||||||
Develops, produces, and
|
|||||||||||
services turbochargers
|
|||||||||||
and large turbocharging
|
|||||||||||
components. The Company
|
|||||||||||
offers turbocharging
|
|||||||||||
technologies and
|
|||||||||||
optimization solutions for
|
|||||||||||
engines thereby reducing
|
|||||||||||
the environmental impact
|
|||||||||||
with less fuel emissions.
|
|||||||||||
(Cost $562,702)
|
|||||||||||
967,219
|
0.76
|
%
|
|||||||||
Metal Fabricate/Hardware — 1.07%
|
|||||||||||
11,000
|
SFS Group AG
|
1,361,849
|
1.07
|
%
|
|||||||
Provides automotive
|
|||||||||||
products, building and
|
|||||||||||
electronic components, flat
|
|||||||||||
roofing and solar fastening
|
|||||||||||
systems. The company
|
|||||||||||
operates production
|
|||||||||||
facilities in Asia, Europe
|
|||||||||||
and North America.
|
|||||||||||
(Cost $719,463)
|
|||||||||||
1,361,849
|
1.07
|
%
|
|||||||||
Packaging & Containers — 1.63%
|
|||||||||||
90,000
|
SIG Combibloc Group AG
|
|
2,069,150
|
1.63
|
%
|
||||||
The company, through its
|
|||||||||||
subsidiaries, manufactures
|
|||||||||||
and produces bottling
|
|||||||||||
machines and systems for
|
|||||||||||
the food and beverage
|
|||||||||||
industries. The company
|
|||||||||||
serves customers
|
|||||||||||
worldwide.
|
|||||||||||
(Cost $1,234,854)
|
|||||||||||
2,069,150
|
1.63
|
%
|
|||||||||
Pharmaceuticals — 21.66%
|
|||||||||||
142,229
|
Novartis AG
|
14,342,037
|
11.31
|
%
|
|||||||
One of the leading
|
|||||||||||
manufacturers of branded
|
|||||||||||
and generic
|
|||||||||||
pharmaceutical products.
|
|||||||||||
(Cost $6,989,680)
|
|||||||||||
45,177
|
Roche Holding AG
|
13,123,955
|
10.35
|
%
|
|||||||
Develops and
|
|||||||||||
manufactures
|
|||||||||||
pharmaceutical and
|
|||||||||||
diagnostic products.
|
|||||||||||
Produces prescription
|
|||||||||||
drugs to treat cardiovascular,
|
|||||||||||
infectious and autoimmune
|
|||||||||||
diseases and for other
|
|||||||||||
areas including dermatology
|
|||||||||||
and oncology.
|
|||||||||||
(Cost $8,109,729)
|
|||||||||||
27,465,992
|
21.66
|
%
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Private Equity — 2.79%
|
|||||||||||
2,450
|
Partners Group
|
||||||||||
Holding AG
|
$
|
3,530,981
|
2.79
|
%
|
|||||||
A global private markets
|
|||||||||||
investment management
|
|||||||||||
firm with investment
|
|||||||||||
programs under
|
|||||||||||
management in private
|
|||||||||||
equity, private real estate,
|
|||||||||||
private infrastructure and
|
|||||||||||
private debt. The firm
|
|||||||||||
manages a broad range of
|
|||||||||||
customized portfolios for
|
|||||||||||
an international clientele of
|
|||||||||||
institutional investors.
|
|||||||||||
Partners Group is
|
|||||||||||
headquartered in Zug,
|
|||||||||||
Switzerland.
|
|||||||||||
(Cost $1,917,144)
|
|||||||||||
3,530,981
|
2.79
|
%
|
|||||||||
Retail — 6.42%
|
|||||||||||
44,000
|
Cie Financiere
|
||||||||||
Richemont SA
|
6,051,209
|
4.77
|
%
|
||||||||
Manufactures and retails
|
|||||||||||
luxury goods. Produces
|
|||||||||||
jewelry, watches, leather
|
|||||||||||
goods, writing instruments
|
|||||||||||
and men’s and
|
|||||||||||
women’s wear.
|
|||||||||||
(Cost $3,421,020)
|
|||||||||||
40,000
|
Swatch Group AG –
|
||||||||||
Registered Shares
|
|
2,093,507
|
1.65
|
%
|
|||||||
Manufactures finished
|
|||||||||||
watches, movements and
|
|||||||||||
components. Produces
|
|||||||||||
components necessary to
|
|||||||||||
its various watch brand
|
|||||||||||
companies. The company
|
|||||||||||
also operates
|
|||||||||||
retail boutiques.
|
|||||||||||
(Cost $2,466,618)
|
|||||||||||
8,144,716
|
6.42
|
%
|
|||||||||
Semiconductors — 1.11%
|
|||||||||||
562,500
|
ams-OSRAM AG1
|
1,412,850
|
1.11
|
%
|
|||||||
Designs and manufactures
|
|||||||||||
advanced sensor solutions.
|
|||||||||||
The company also delivers
|
|||||||||||
a broad range of
|
|||||||||||
technology solutions for
|
|||||||||||
consumer electronics and
|
|||||||||||
communication device
|
|||||||||||
manufactures.
|
|||||||||||
(Cost $1,958,569)
|
|||||||||||
1,412,850
|
1.11
|
%
|
|||||||||
Transportation — 1.55%
|
|||||||||||
5,720
|
Kuehne + Nagel
|
||||||||||
International AG
|
1,969,531
|
1.55
|
%
|
||||||||
Transports freight
|
|||||||||||
worldwide. The company
|
|||||||||||
operates sea, land, and
|
|||||||||||
rail freight transportation
|
|||||||||||
businesses and warehousing
|
|||||||||||
and distribution facilities.
|
|||||||||||
(Cost $1,558,223)
|
|||||||||||
1,969,531
|
1.55
|
%
|
|||||||||
Total Common Stock
|
|||||||||||
(Cost $84,164,395)
|
124,022,336
|
97.78
|
%
|
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Preferred Stock — 0.00%
|
|||||||||||
Industrial Goods & Services — 0.00%
|
|||||||||||
500,863
|
SelFrag AG Class A1,2,3
|
$
|
5,178
|
0.00
|
%
|
||||||
Designs, manufactures
|
|||||||||||
and sells industrial
|
|||||||||||
machines and processes
|
|||||||||||
using selective
|
|||||||||||
fragmentation technology.
|
|||||||||||
(Cost $1,932,198)
|
|||||||||||
5,178
|
0.00
|
%
|
|||||||||
Total Preferred Stock
|
|||||||||||
(Cost $1,932,198)
|
5,178
|
0.00
|
%
|
||||||||
Limited Partnership — 0.79%
|
|||||||||||
Biotechnology — 0.79%
|
|||||||||||
3,294,705
|
Aravis Biotech II, Limited
|
||||||||||
Partnership1,3,4
|
997,278
|
0.79
|
%
|
||||||||
Makes early stage venture
|
|||||||||||
investments in the
|
|||||||||||
biotechnology &
|
|||||||||||
pharmaceuticals industry.
|
|||||||||||
(Cost $213,885)
|
|||||||||||
997,278
|
0.79
|
%
|
|||||||||
Total Limited
|
|||||||||||
Partnership
|
|||||||||||
(Cost $213,885)
|
997,278
|
0.79
|
%
|
||||||||
Total Investments5
|
|||||||||||
(Cost $86,310,478)
|
125,024,792
|
98.57
|
%
|
||||||||
Other Assets
|
|||||||||||
Less Liabilities5
|
1,806,464
|
1.43
|
%
|
||||||||
Net Assets
|
$
|
126,831,256
|
100.00
|
%
|
|||||||
Net Asset Value Per Share:
|
|||||||||||
($126,831,256 ÷
|
|||||||||||
shares outstanding,
|
|||||||||||
$0.001 par value:
|
|||||||||||
shares authorized)
|
$
|
|
Schedule of Investments by Industry
|
December 31, 2023
|
(continued)
|
1
|
Non-income producing security.
|
2
|
Value determined using significant unobservable inputs.
|
3
|
Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced at Fair Value in accordance with
the Fund’s valuation policy and procedures. Aravis Biotech II, Limited Partnership was valued at net asset value as a practical expedient for fair value. At the end of the period, the aggregate Fair Value of these securities amounted to
$1,346,338 or 1.06% of the Fund’s net assets. Additional information on these securities is as follows:
|
Security
|
Acquisition Date
|
Cost
|
||||
Aravis Biotech II, Limited Partnership
|
July 31, 2007 – May 29, 2018
|
$
|
213,885
|
|||
Eyesense AG – Common Shares
|
July 22, 2010 – October 3, 2011
|
3,007,048
|
||||
SelFrag AG – Class A – Preferred Shares
|
December 15, 2011 – January 28, 2014
|
1,932,198
|
||||
Spineart SA – Common Shares
|
December 22, 2010 - December 20, 2020
|
1,554,486
|
||||
$
|
6,707,617
|
4
|
Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company’s outstanding voting securities or an equivalent interest in the company.
Details related to affiliated company holdings are as follows:
|
Limited Partnership – 0.79% | |
Biotechnology – 0.79%
|
Value
|
Change in
|
Value
|
Shares
|
||||||||||||||||||||||||||||||||||
as of
|
Gross
|
Gross
|
Corporate
|
Realized
|
Unrealized
|
Interest
|
as of
|
as of
|
|||||||||||||||||||||||||||||
Name of Issuer
|
12/31/22
|
Additions
|
Reductions
|
Actions
|
Gain/(Loss)
|
Gain/(Loss)
|
Income
|
12/31/23
|
12/31/23
|
||||||||||||||||||||||||||||
Aravis Biotech II,
|
|||||||||||||||||||||||||||||||||||||
Limited Partnership1,3
|
$
|
1,302,142
|
$
|
—
|
$
|
(1,814,239
|
)
|
$
|
—
|
$
|
217,940
|
$
|
1,291,435
|
$
|
—
|
$
|
997,278
|
3,294,705
|
|||||||||||||||||||
$
|
1,302,142
|
$
|
—
|
$
|
(1,814,239
|
)
|
$
|
—
|
$
|
217,940
|
$
|
1,291,435
|
$
|
—
|
$
|
997,278
|
3,294,705
|
5
|
All of the Fund’s investments and other assets are pledged as collateral in accordance with a credit agreement with U.S. Bank, National Association.
|
Schedule of Investments by Industry
|
December 31, 2023
|
(concluded)
|
PORTFOLIO HOLDINGS
|
||||
% of Net Assets as of December 31, 2023
|
||||
Pharmaceuticals
|
21.66
|
%
|
||
Food
|
20.70
|
%
|
||
Insurance
|
8.32
|
%
|
||
Healthcare-Products
|
7.30
|
%
|
||
Retail
|
6.42
|
%
|
||
Diversified Financial Services
|
3.27
|
%
|
||
Biotechnology
|
3.07
|
%
|
||
Banks
|
3.03
|
%
|
||
Building Materials
|
2.96
|
%
|
||
Private Equity
|
2.79
|
%
|
||
Electronic Components & Equipment
|
2.73
|
%
|
||
Health Care
|
2.34
|
%
|
||
Computers
|
1.68
|
%
|
||
Packaging & Containers
|
1.63
|
%
|
||
Transportation
|
1.55
|
%
|
||
Electric
|
1.54
|
%
|
||
Industrials
|
1.38
|
%
|
||
Chemicals
|
1.34
|
%
|
||
Advertising
|
1.15
|
%
|
||
Semiconductors
|
1.11
|
%
|
||
Metal Fabricate/Hardware
|
1.07
|
%
|
||
Healthcare - Services
|
0.77
|
%
|
||
Machinery-Diversified
|
0.76
|
%
|
||
Industrial Goods & Services
|
0.00
|
%
|
||
Other Assets Less Liabilities
|
1.43
|
%
|
||
100.00
|
%
|
|||
TOP 10 PORTFOLIO HOLDINGS
|
||||
% of Net Assets as of December 31, 2023
|
||||
Nestle SA
|
17.71
|
%
|
||
Novartis AG
|
11.31
|
%
|
||
Roche Holding AG
|
10.35
|
%
|
||
Cie Financiere Richemont SA
|
4.77
|
%
|
||
Zurich Insurance Group AG
|
4.32
|
%
|
||
UBS Group AG
|
2.84
|
%
|
||
Partners Group Holding AG
|
2.79
|
%
|
||
Sika AG
|
2.15
|
%
|
||
Alcon, Inc.
|
2.09
|
%
|
||
Tecan Group AG
|
1.86
|
%
|
Statement of Assets and Liabilities
|
December 31, 2023
|
Assets:
|
||||
Investments in unaffiliated issuers, at value (cost $86,096,593)
|
$
|
124,027,514
|
||
Investments in affiliated issuers, at value (cost $213,885)
|
997,278
|
|||
Total Investments, at value (cost $86,310,478)
|
125,024,792
|
|||
Cash and cash equivalents
|
669,256
|
|||
Foreign currency (cost $23,330)
|
23,446
|
|||
Tax reclaims receivable
|
1,431,019
|
|||
Interest receivable
|
449
|
|||
Prepaid expenses
|
19,919
|
|||
Total assets
|
127,168,881
|
|||
Liabilities:
|
||||
Accrued Fees and Expenses:
|
||||
Investment advisory
|
76,679
|
|||
Directors
|
76,567
|
|||
Legal
|
19,484
|
|||
Audit
|
55,505
|
|||
Custody
|
8,786
|
|||
Credit facility interest
|
32,313
|
|||
Other
|
68,291
|
|||
Total liabilities
|
337,625
|
|||
Net assets
|
$
|
126,831,256
|
||
Composition of Net Assets:
|
||||
Paid-in capital
|
88,205,751
|
|||
Total distributable earnings
|
38,625,505
|
|||
Net assets
|
$
|
126,831,256
|
||
Net Asset Value Per Share:
|
||||
($126,831,256 ÷
shares outstanding, |
||||
$0.001 par value:
shares authorized) |
$
|
|
Statement of Operations
|
For the Year Ended December 31, 2023
|
Investment Income:
|
||||
Dividend (less of foreign tax withheld of $489,651)
|
$
|
2,912,736
|
||
Interest income
|
30,945
|
|||
Total income
|
2,943,681
|
|||
Expenses:
|
||||
Investment advisory fees (Note 2)
|
861,972
|
|||
Directors’
|
309,335
|
|||
Legal (Note 3)
|
137,839
|
|||
Officers
|
136,129
|
|||
Administration (Note 3)
|
130,133
|
|||
Delaware franchise tax (Note 9)
|
81,200
|
|||
Credit facility interest
|
69,508
|
|||
Printing and shareholder reports
|
63,086
|
|||
Audit (Note 3)
|
55,505
|
|||
Custody (Note 3)
|
58,059
|
|||
Insurance
|
48,465
|
|||
Transfer agency (Note 3)
|
36,477
|
|||
Miscellaneous
|
59,670
|
|||
Total expenses
|
2,047,378
|
|||
Net investment income
|
896,303
|
|||
Realized and Unrealized Gains on Investments and Foreign Currency Translations:
|
||||
Net realized gain from:
|
||||
Investments in unaffiliated issuers
|
3,634,014
|
|||
Investments in affiliated issuers
|
217,940 |
|||
Foreign currency transactions
|
205,218
|
|||
Total net realized gain from unaffiliated and
|
||||
affiliated issuers and foreign currency transactions
|
4,057,172
|
|||
Net change in unrealized appreciation from:
|
||||
Investments in unaffiliated issuers
|
12,473,373
|
|||
Investments in affiliated issuers
|
1,291,435
|
|||
Foreign currency translations
|
114,814
|
|||
Total net change in unrealized appreciation from
|
||||
unaffiliated and affiliated issuers, and foreign currency translations
|
13,879,622
|
|||
Net Realized and Unrealized Gain on
|
||||
Investments and Foreign Currency Translations
|
17,936,794
|
|||
Net Increase in Net Assets from Operations
|
$
|
18,833,097
|
Statement of Cash Flows
|
For the Year Ended December 31, 2023
|
Cash flows from operating activities:
|
||||
Net increase in net assets applicable to common shareholders
|
$
|
18,833,097
|
||
Adjustments to reconcile net increase in net assets applicable to
|
||||
common shareholders resulting from operations to net cash
|
||||
provided by operating activities:
|
||||
Purchases of investments
|
(16,922,326
|
)
|
||
Proceeds from sales of investments
|
22,216,493
|
|||
Net purchases and sales of short-term investments
|
331,030
|
|
||
Return of capital distributions received from underlying investments
|
1,603,806
|
|||
Increase in tax reclaims receivable
|
(133,131
|
)
|
||
Decrease in dividends and interest receivable
|
2,498
|
|||
Decrease in other assets
|
517
|
|||
Increase in payable to Adviser
|
6,422
|
|||
Increase in accrued expenses and other liabilities
|
6,788
|
|||
Net realized gains from investments
|
(3,851,954
|
)
|
||
Net change in unrealized appreciation (depreciation) from investments
|
(13,764,808
|
)
|
||
Net cash provided by operating activities
|
8,328,432
|
|||
Cash flows from financing activities:
|
||||
Distributions paid to common shareholders
|
(6,488,430
|
)
|
||
Repurchase of common stock
|
(1,687,724
|
)
|
||
Net cash used in financing activities
|
(8,176,154
|
)
|
||
Net change in cash
|
$
|
152,278
|
|
|
Cash:
|
||||
Beginning of year*
|
540,424
|
|||
End of year*
|
$
|
692,702
|
||
Cash financing activities not included herein consist of interest paid
|
44,506
|
*
|
Cash included in the Statement of Cash Flows comprise of foreign currency and Money Market Deposit Account.
|
For the
|
For the
|
|||||||
Year Ended
|
Year Ended
|
|||||||
December 31, 2023
|
December 31, 2022
|
|||||||
Increase (Decrease) in Net Assets:
|
||||||||
Operations:
|
||||||||
Net investment income
|
$
|
896,303
|
$
|
920,814
|
||||
Total net realized gain from unaffiliated and
|
||||||||
affiliated issuers and foreign currency transactions
|
4,057,172
|
2,080,182
|
||||||
Total net change in unrealized appreciation
|
||||||||
(depreciation) from unaffiliated and affiliated issuers,
|
||||||||
foreign currency and foreign currency translations
|
13,879,622
|
(30,399,182
|
)
|
|||||
Net increase (decrease) in net assets from operations
|
18,833,097
|
(27,398,186
|
)
|
|||||
Distributions to Stockholders:
|
||||||||
From earnings
|
(5,796,462
|
)
|
(2,977,194
|
)
|
||||
From return of capital
|
(691,968
|
)
|
(5,241,653
|
)
|
||||
Total distributions to stockholders
|
(6,488,430
|
)
|
(8,218,847
|
)
|
||||
Capital Stock Transactions:
|
||||||||
Value of shares repurchased through
|
||||||||
stock repurchase program (Note 6)
|
(1,687,724
|
)
|
(120,928
|
)
|
||||
Total decrease from capital share transactions
|
(1,687,724
|
)
|
(120,928
|
)
|
||||
Total increase (decrease) in net assets
|
10,656,943
|
(35,737,961
|
)
|
|||||
Net Assets:
|
||||||||
Beginning of year
|
116,174,313
|
151,912,274
|
||||||
End of year
|
$
|
126,831,256
|
$
|
116,174,313
|
For the Years Ended December 31,
|
||||||||||||||||||||
2023
|
2022
|
2021
|
2020
|
2019
|
||||||||||||||||
Per Share Operating Performance:
|
||||||||||||||||||||
Net asset value at the beginning of year
|
$
|
8.80
|
$
|
11.50
|
$
|
10.45
|
$
|
9.71
|
$
|
7.96
|
||||||||||
Income from Investment Operations:
|
||||||||||||||||||||
Net investment income1
|
0.07
|
0.07
|
0.05
|
0.05
|
0.01
|
|||||||||||||||
Net realized and unrealized
|
||||||||||||||||||||
gain (loss) on investments2
|
1.36
|
(2.15
|
)
|
1.58
|
1.24
|
1.88
|
||||||||||||||
Total from investment activities
|
1.43
|
(2.08
|
)
|
1.63
|
1.29
|
1.89
|
||||||||||||||
Anti-dilutive effect of common
|
||||||||||||||||||||
share repurchase program
|
0.03
|
0.00
|
4
|
—
|
0.01
|
—
|
||||||||||||||
Less Distributions:
|
||||||||||||||||||||
Net investment income
|
(0.17
|
)
|
(0.06
|
)
|
(0.06
|
)
|
(0.08
|
)
|
(0.12
|
)
|
||||||||||
Net realized gains
|
(0.28
|
)
|
(0.16
|
)
|
(0.09
|
)
|
—
|
(0.02
|
)
|
|||||||||||
Return of Capital
|
(0.05
|
)
|
(0.40
|
)
|
(0.43
|
)
|
(0.48
|
)
|
—
|
|||||||||||
Total distributions
|
(0.50
|
)
|
(0.62
|
)
|
(0.58
|
)
|
(0.56
|
)
|
(0.14
|
)
|
||||||||||
Net asset value at end of year
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Market value per share at the end of year
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Total Investment Returns:3
|
||||||||||||||||||||
Based on market value per share
|
15.48
|
%
|
-17.62
|
%
|
18.25
|
%
|
14.18
|
%
|
24.00
|
%
|
||||||||||
Based on net asset value per share
|
16.92
|
%
|
-17.97
|
%
|
16.09
|
%
|
14.29
|
%
|
23.80
|
%
|
||||||||||
Ratios to Average Net Assets:
|
||||||||||||||||||||
Net expenses
|
1.66
|
%6
|
1.68
|
%5
|
1.40
|
%
|
1.80
|
%
|
2.13
|
%
|
||||||||||
Gross expenses
|
1.66
|
%6
|
1.68
|
%5
|
1.40
|
%
|
1.80
|
%
|
2.13
|
%
|
||||||||||
Net investment income
|
0.73
|
%
|
0.74
|
%
|
0.48
|
%
|
0.48
|
%
|
0.10
|
%
|
||||||||||
Supplemental Data and Ratios
|
||||||||||||||||||||
Net assets at end of year (000’s)
|
$
|
126,831
|
$
|
116,174
|
$
|
151,912
|
$
|
138,040
|
$
|
128,864
|
||||||||||
Average net assets during the year (000’s)
|
$
|
123,139
|
$
|
123,684
|
$
|
144,019
|
$
|
125,666
|
$
|
118,960
|
||||||||||
Portfolio turnover rate
|
14
|
%
|
15
|
%
|
11
|
%
|
12
|
%
|
18
|
%
|
1
|
Calculated using the average shares method.
|
2
|
Includes net realized and unrealized currency gains and losses.
|
3
|
Total investment return based on market value differs from total investments return based on net asset value due to changes in the relationship between the market value of the Fund’s shares
and its NAV per share.
|
4
|
Less than 0.5 cents per share.
|
5
|
If interest expense and commitment fees had been excluded, the expense ratios would have been lower by 0.05% for the year ended December 31, 2022.
|
6 |
If interest expense and commitment fees had been excluded, the expense ratios would have been lower by 0.06% for the year ended December 31, 2023.
|
Level 1—
|
unadjusted quoted prices in active markets for identical assets and liabilities
|
Level 2—
|
other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)
|
Level 3—
|
significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)
|
Level 2
|
Level 3
|
Investments
|
||||||||||||||||||
Level 1
|
Other Significant
|
Significant
|
Valued at
|
|||||||||||||||||
Quoted Prices
|
Observable Inputs
|
Unobservable Inputs
|
NAV**
|
Total
|
||||||||||||||||
Investments in Securities*
|
||||||||||||||||||||
Common Stock
|
$
|
122,681,176
|
$
|
—
|
$
|
1,341,160
|
$
|
—
|
$
|
124,022,336
|
||||||||||
Preferred Stock
|
—
|
—
|
5,178
|
—
|
5,178
|
|||||||||||||||
Limited Partnership
|
—
|
—
|
—
|
997,278
|
997,278
|
|||||||||||||||
Total Investments in Securities
|
$
|
122,681,176
|
$
|
—
|
$
|
1,346,338
|
$
|
997,278
|
$
|
125,024,792
|
*
|
Please see the Schedule of Investments for industry classifications.
|
**
|
As of December 31, 2023, certain of the Fund’s investments were valued using net asset value (“NAV”) per share (or its equivalent) as a practical expedient for fair value and have been
excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented in the
statement of assets and liabilities.
|
Value at
|
||||||||||
December 31, 2023
|
Valuation Technique
|
Unobservable Inputs
|
Range1
|
|||||||
Healthcare-Products
|
||||||||||
EyeSense AG, Series A—Common Shares
|
$
|
1,490
|
Market approach
|
Based on expected sale
|
N/A
|
|||||
proceeds due to sale back
|
||||||||||
of shares of Eyesense
|
||||||||||
Spineart SA—Common Shares
|
1,339,670
|
Market approach
|
Based on listed trading
|
15-25
|
%
|
|||||
multiples, cross checked to
|
||||||||||
secondary share purchase
|
||||||||||
with additional discount for
|
||||||||||
lack of marketability
|
||||||||||
Industrial Goods & Services
|
||||||||||
SelFrag AG Class A—Preferred Shares
|
5,178
|
Market approach
|
Based on expected sale
|
N/A
|
||||||
proceeds due to sale back
|
||||||||||
of shares of Selfrag
|
||||||||||
Total
|
$
|
1,346,338
|
1
|
Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. A change in the discount rate is accompanied by a directionally opposite
change in fair value.
|
Common
|
Preferred
|
|||||||||||
Stock
|
Stock
|
Total
|
||||||||||
Balance as of December 31, 2022
|
$
|
1,384,260
|
$
|
48,722
|
$
|
1,432,982
|
||||||
Change in Unrealized Appreciation/Depreciation
|
(43,100
|
)
|
(43,544
|
)
|
(86,644
|
)
|
||||||
Net Realized Gain (Loss)
|
—
|
—
|
—
|
|||||||||
Gross Purchases
|
—
|
—
|
—
|
|||||||||
Gross Sales
|
—
|
—
|
—
|
|||||||||
Transfer out of Level 3
|
—
|
—
|
—
|
|||||||||
Balance as of December 31, 2023
|
$
|
1,341,160
|
$
|
5,178
|
$
|
1,346,338
|
||||||
Change in unrealized appreciation (depreciation) during the period
|
||||||||||||
for Level 3 investments held at December 31, 2023
|
(43,100
|
)
|
(43,544
|
)
|
(86,644
|
)
|
For the Year Ended
|
For the Year Ended
|
|||||||||||||||
December 31, 2023
|
December 31, 2022
|
|||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||
Dividends Reinvested
|
—
|
$
|
—
|
—
|
$
|
—
|
||||||||||
Repurchased through Stock Repurchase Program (Note 6)
|
(205,045
|
)
|
(1,687,724
|
)
|
(16,504
|
)
|
(120,928
|
)
|
||||||||
Repurchased from Tender Offer (Note 7)
|
—
|
—
|
—
|
—
|
||||||||||||
Net Increase/(Decrease)
|
(205,045
|
)
|
$
|
(1,687,724
|
)
|
(16,504
|
)
|
$
|
(120,928
|
)
|
2023
|
2022
|
|||||||
Ordinary Income
|
$
|
2,489,577
|
$
|
810,137
|
||||
Return of Capital
|
691,968
|
5,241,653
|
||||||
Long-Term Capital Gains
|
3,306,885
|
2,167,057
|
||||||
Total
|
$
|
6,488,430
|
$
|
8,218,847
|
Tax cost of investments
|
$
|
86,488,037
|
||
Unrealized appreciation
|
48,523,318
|
|||
Unrealized depreciation
|
(9,986,563
|
)
|
||
Net unrealized appreciation
|
38,536,755
|
|||
Net unrealized on foreign currency
|
119,189
|
|||
Undistributed ordinary income
|
—
|
|||
Undistributed long-term capital gains
|
—
|
|||
Distributable earnings
|
—
|
|||
Other accumulated losses
|
(30,439
|
)
|
||
Total distributable earnings
|
$
|
38,625,505
|
Record Date
|
Payable Date
|
Ordinary Income
|
Return of Capital
|
ST Cap Gains
|
LT Cap Gains
|
Total Distribution
|
|||||||||||||||
3/22/23
|
3/31/23
|
$
|
0.04139848
|
$
|
0.01310152
|
$
|
0.00574
|
$
|
0.06261
|
$
|
0.12285
|
||||||||||
6/21/23
|
6/30/23
|
0.04139848
|
0.01310152
|
0.00574
|
0.06261
|
0.12285
|
|||||||||||||||
9/20/23
|
9/29/23
|
0.04139848
|
0.01310152
|
0.00574
|
0.06261
|
0.12285
|
|||||||||||||||
12/19/23
|
12/29/23
|
0.04346261
|
0.01375739
|
0.00603
|
0.06575
|
0.12900
|
|||||||||||||||
$
|
0.49755
|
Original Capital
|
Unfunded
|
|||||||
Investments
|
Commitment*
|
Commitment*
|
||||||
Private Equity Limited Partnership—International(a)
|
||||||||
Aravis Biotech II, Limited Partnership
|
$
|
3,861,463
|
$
|
—
|
*
|
The original capital commitment represents 3,250,000 Swiss francs, which has been fully funded as of December 31, 2023. The Swiss franc/U.S. dollar exchange rate as of December 31, 2023 was
used for conversion and equaled 0.84165 as of such date.
|
(a)
|
This category consists of one private equity limited partnership that invests primarily in venture capital companies in the biotechnology and medical technology sectors. There is no
redemption right for the interest in this limited partnership. Instead, the nature of investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.
|
Weighted
|
|||||
Maximum Amount
|
Average Daily
|
Maximum Amount
|
Interest
|
Commitment
|
Average
|
Available
|
Borrowings
|
Outstanding
|
Expense
|
Fee
|
Interest Rate
|
$15,000,000
|
$319,203
|
$4,811,000
|
$21,036
|
$48,472
|
6.50%
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Gross Foreign
|
Foreign Taxes
|
Gross Foreign
|
Foreign Taxes
|
Shares Outstanding
|
Source Income
|
Pass-through
|
Source Income Per Share
|
Pass-through Per Share
|
at 12/31/23
|
3,402,387
|
489,651
|
0.26190932
|
0.03769238
|
12,990,705
|
Position(s)
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Held By Director
|
Address1 & Age
|
(Since)
|
During At Least The Past Five Years
|
During At Least The Past Five Years
|
Class I
|
|||
Richard Dayan
|
Director (2018);
|
President and owner of
|
Trustee of High Income Securities
|
Member of the
|
Cactus Trading since 1990
|
Fund since 2018
|
|
Age: 80
|
Audit Committee (2018);
|
||
Member of the
|
|||
Governance/
|
|||
Nominating
|
|||
Committee (2018)
|
|||
Moritz A. Sell
|
Director (2017);
|
Principal, Edison Holdings GmbH;
|
Trustee of High Income Securities
|
Member and
|
Senior Advisor, Markston
|
Fund since 2018; Director of FAX
|
|
Age: 56
|
Chair of the Audit
|
International LLC until 2019; Director,
|
(Aberdeen Asia Pacific Income
|
Committee (2017);
|
Market Strategist and Head of
|
Fund) and FCO (Aberdeen Global
|
|
Lead Independent
|
Proprietary Trading (London Branch),
|
Income Fund) since 2018; Director of
|
|
Director (2018)
|
Landesbank Berlin AG and
|
IAF (Aberdeen Australia Equity Fund)
|
|
Landesbank Berlin Holding AG
|
since 2004; Director of Aberdeen
|
||
(formerly, Bankgesellschaft Berlin AG)
|
Greater China Fund until 2018;
|
||
from 1996 to 2013
|
Chairman and Director of
|
||
Aberdeen Singapore Fund
|
|||
until 2018
|
|||
Class II
|
|||
Andrew Dakos*
|
Director
|
Partner, Bulldog Investors, LLP;
|
President and Director of Special
|
(2017) and
|
Partner, Ryan Heritage, LLP;
|
Opportunities Fund, Inc. since
|
|
Age: 57
|
Chairman (2018)
|
Principal of the former general partner
|
2009; Trustee, Crossroads
|
of several private investment
|
Liquidating Trust (formerly,
|
||
partnerships in the Bulldog
|
Crossroads Capital, Inc.) from
|
||
Investors group of private funds;
|
2015-2020; President and Trustee of
|
||
Principal of the managing general
|
High Income Securities Fund since
|
||
partner of Bulldog Investors
|
2018; Director, Brookfield DTLA
|
||
General Partnership
|
Fund Office Trust Investor Inc.
|
||
since 2017
|
*
|
Mr. Dakos is considered an “interested person” of the Fund within the meaning of the 1940 Act (and a Class II Interested Director of the Fund) as a result of his position as President and
Chief Executive Officer of the Fund.
|
Position(s)
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Held By Director
|
Address1 & Age
|
(Since)
|
During At Least The Past Five Years
|
During At Least The Past Five Years
|
Class III
|
|||
Phillip F. Goldstein
|
Director (2018);
|
Partner of Bulldog Investors, LLP
|
Chairman and Director of The
|
Member and
|
since 2009; Partner of Ryan
|
Mexico Equity and Income Fund,
|
|
Age: 79
|
Chair of the
|
Heritage, LLP; Principal of the former
|
Inc. since 2000; Chairman,
|
Governance/
|
general partner of several private
|
Director and Secretary of Special
|
|
Nominating
|
investment partnerships in the
|
Opportunities Fund, Inc. since
|
|
Committee (2018)
|
Bulldog Investors group of private
|
2009; Chairman, Trustee and Secretary
|
|
funds since 2009; Principal of the
|
of High Income Securities Fund since
|
||
managing general partner of
|
2018; Director of Brookfield DTLA
|
||
Bulldog Investors General Partnership
|
Fund Office Trust Investor Inc.
|
||
since 2017; MVC Capital, Inc. from
|
|||
2012-2020; Trustee of Crossroads
|
|||
Liquidating Trust (formerly,
|
|||
Crossroads Capital, Inc.) from
|
|||
2016-2020
|
|||
Gerald Hellerman
|
Director (2018);
|
Chief Compliance Officer of
|
Director of Mexico Equity and
|
Member of the
|
The Mexico Equity and Income Fund,
|
Income Fund, Inc. since 2001;
|
|
Age: 86
|
Audit Committee
|
Inc. from 2001 through March 31,
|
Special Opportunities Fund, Inc.
|
(2018); Member
|
2020 and Special Opportunities
|
since 2009; Fiera Capital Series Trust
|
|
and Chair of the
|
Fund, Inc. from 2009 through
|
from 2017-2023; Trustee of High
|
|
Pricing Committee
|
March 31, 2020; Managing Director
|
Income Securities Fund since 2018;
|
|
(2018)
|
of Hellerman Associates (a financial
|
MVC Capital, Inc. from
|
|
and corporate consulting firm)
|
2003-2020; Trustee of Crossroads
|
||
since 1993 (which terminated
|
Liquidating Trust (formerly, Crossroads
|
||
activities as of December 31, 2013)
|
Capital, Inc.) from 2017-2020
|
Officers2
|
|||
Name,
|
Position(s)
|
Term of Office and
|
Principal Occupation(s)
|
Address1 & Age
|
with Fund
|
Length of Time Served
|
During At Least The Past Five Years
|
Andrew Dakos
|
President and
|
President and Chief
|
Partner, Bulldog Investors, LLP;
|
Chief Executive
|
Executive Officer since 2019;
|
Partner, Ryan Heritage, LLP;
|
|
Age: 57
|
Officer; Director
|
Chairman since 2018;
|
Principal of the former general
|
and Chairman.
|
Director since 2017
|
partner of several private
|
|
investment partnerships in the
|
|||
Bulldog Investors group of private
|
|||
funds; Principal of the managing
|
|||
general partner of Bulldog
|
|||
Investors General Partnership
|
|||
Thomas Antonucci
|
Chief Financial
|
Since 2019
|
Director of Operations,
|
Officer
|
Bulldog Investors, LLP;
|
||
Age: 55
|
Chief Financial Officer
|
||
and Treasurer of Special
|
|||
Opportunities Fund; Treasurer
|
|||
of High Income Securities Fund
|
|||
Stephanie Darling
|
Chief Compliance
|
Since 2019
|
General Counsel and Chief
|
Officer
|
Compliance Officer of Bulldog
|
||
Age: 53
|
Investors, LLP; Chief Compliance
|
||
Officer of Ryan Heritage, LLP,
|
|||
High Income Securities
|
|||
Fund, Special Opportunities Fund,
|
|||
Inc., and Mexico Equity and
|
|||
Income Fund, Inc.; Principal of The
|
|||
Law Office of Stephanie Darling;
|
|||
Editor-in-Chief of The
|
|||
Investment Lawyer
|
|||
Rajeev Das
|
Secretary
|
Since 2019
|
Head of Trading, Bulldog
|
Investors, LLP
|
|||
Age: 55
|
1
|
The address for each Director and Executive Officer is c/o The Swiss Helvetia Fund, Inc., 615 East Michigan Street, Milwaukee, WI 53202.
|
||
2
|
Each Executive Officer serves on a year-to-year basis for an indefinite term, until his or her successor is elected and qualified.
|
Andrew Dakos
|
Gerald Hellerman1,4
|
Chairman, President and
|
Director
|
Chief Executive Officer
|
Thomas Antonucci
|
Richard Dayan1,5
|
Chief Financial Officer
|
Director
|
Stephanie Darling
|
Phillip Goldstein2
|
Chief Compliance Officer
|
Director
|
Rajeev Das
|
Moritz Sell3,6
|
Secretary
|
Director
|
1
|
Audit Committee Member
|
4
|
Pricing Committee Chair
|
2
|
Governance Nominating
|
5
|
Governance Committee
|
Committee Chair
|
Member
|
||
3
|
Audit Committee Chair
|
6
|
Lead Independent Director
|
Number of
Accounts
|
Total Assets in
Accounts
|
Number of Accounts
where Advisory Fee
is Based on Account
Performance
|
Total Assets in
Accounts where
Advisory Fee is
Based on Account
Performance
|
|
Stefan
Frischknecht
|
|
|
|
|
Registered
Investment
Companies
|
None
|
None
|
None
|
None
|
Other Pooled
Investment
Vehicles
|
2
|
$60,007,941
|
None
|
None
|
Other Accounts
|
3
|
$997,967,010
|
None
|
None
|
Daniel Lenz
|
|
|
|
|
Registered
Investment
Companies
|
None
|
None
|
None
|
None
|
Other Pooled
Investment
Vehicles
|
4
|
$784,850,126
|
None
|
None
|
Other Accounts
|
4
|
$829,364,023
|
None
|
None
|
Period
|
(a)
Total Number of
Shares (or Units)
Purchased
|
(b)
Average Price Paid
per Share (or Unit)
|
(c)
Total Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs
|
(d)
Maximum Number
(or Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
|
7/1/23 – 7/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
8/1/23 – 8/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
9/1/23 – 9/30/23
|
N/A
|
N/A
|
N/A
|
N/A
|
10/1/23 – 10/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
11/1/23 – 11/30/23
|
N/A
|
N/A
|
N/A
|
N/A
|
12/1/23 – 12/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
Total
|
(a)
|
The Registrant’s President and Chief Executive Officer and Chief Financial Officer have reviewed the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “Act”)) as
of a date within 90 days of the filing of this report, as required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d‑15(b) under the Securities Exchange Act of 1934. Based on their review, such officers have concluded that the
disclosure controls and procedures are effective in ensuring that information required to be disclosed in this report is appropriately recorded, processed, summarized and reported and made known to them by others within the Registrant and
by the Registrant’s service provider.
|
(b)
|
There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Registrant's internal control over financial reporting.
|
I.
|
Covered Officers/Purpose of the Code
|
•
|
honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional
relationships;
|
•
|
full, fair, accurate, timely and understandable disclosure in reports and documents that the Fund files with, or submits to, the Securities and
Exchange Commission (the "SEC") and in other public communications made by the Fund;
|
•
|
compliance with applicable laws and governmental rules and regulations;
|
•
|
the prompt internal reporting of violations of the Code to an appropriate person or persons identified in the Code; and
|
•
|
accountability for adherence to the Code.
|
II.
|
Covered Officers Should Handle Ethically Actual and Apparent Conflicts of Interest
|
•
|
not use his personal influence or personal relationships improperly to influence investment decisions or financial reporting by the Fund whereby the
Covered Officer would benefit personally to the detriment of the Fund;
|
•
|
not cause the Fund to take action, or fail to take action, for the individual personal benefit of the Covered Officer rather than the benefit of the
Fund; and
|
•
|
not retaliate against any employee or Covered Officer for reports of potential violations that are made in good faith.
|
III.
|
Disclosure and Compliance
|
•
|
Each Covered Officer should familiarize himself with the disclosure requirements and disclosure controls and procedures generally applicable to the
Fund within his area of responsibility;
|
•
|
each Covered Officer should not knowingly misrepresent, or cause others to misrepresent, facts about the Fund to others, whether within or outside
the Fund, including to the Fund's Board members and auditors, and to governmental regulators and self-regulatory organizations; and
|
•
|
to the extent appropriate within his area of responsibility, each Covered Officer should consult with other officers and employees of the Fund and
the Advisor and take other appropriate steps with the goal of promoting full, fair, accurate, timely and understandable disclosure in the reports and documents the Fund files with, or submits to, the SEC and in other public communications
made by the Fund; and
|
•
|
it is the responsibility of each Covered Officer to promote compliance with the standards and restrictions imposed by applicable laws, rules and
regulations.
|
IV.
|
Reporting and Accountability
|
•
|
upon adoption of the Code (or thereafter, as applicable, upon becoming a Covered Officer), affirm in writing to the Board that he has received,
read, and understands the Code;
|
•
|
annually thereafter affirm to the Board that he has complied with the requirements of the Code; and
|
•
|
notify the Audit Committee (the "Committee") promptly if he knows of any violation of the Code. Failure to do so is itself a violation of the Code.
|
•
|
the Committee will take all appropriate action to investigate any potential violations reported to it;
|
•
|
if, after such investigation, the Committee believes that no violation has occurred, the Committee is not required to take any further action;
|
•
|
if the Committee determines that a violation has occurred, it will inform and make a recommendation to the Board, which will consider appropriate
action, which may include review of, and appropriate modifications to, applicable policies and procedures; notification to appropriate personnel of the Advisor or its board; or a recommendation to dismiss the Covered Officer; and
|
•
|
any waivers of or amendments to the Code, to the extent required, will be disclosed as provided by SEC rules.
|
V.
|
Other Policies and Procedures
|
VI.
|
Amendments
|
VII.
|
Confidentiality
|
VIII.
|
Internal Use
|
Andrew Dakos
|
Principal Executive Officer
|
Thomas Antonucci
|
Principal Financial Officer |
1.
|
I have reviewed this report on Form N-CSR of The Swiss Helvetia Fund, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this
report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
|
Date: 3/5/2024
|
/s/Andrew Dakos
Andrew Dakos President and Chief Executive Officer |
1.
|
I have reviewed this report on Form N-CSR of The Swiss Helvetia Fund, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this
report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
|
Date: 3/5/2024
|
/s/Thomas Antonucci
Thomas Antonucci Chief Financial Officer
|
/s/Andrew Dakos
Andrew Dakos
President and Chief Executive Officer,
The Swiss Helvetia Fund, Inc.
|
/s/Thomas Antonucci
Thomas Antonucci
Chief Financial Officer,
The Swiss Helvetia Fund, Inc.
|
Dated: 3/5/2024
|
DISTRIBUTION ESTIMATES
|
Current Distribution | 2023 Fiscal Year * |
|
Per Share
Amount
|
% of
Current
Distribution
|
Per Share
Amount
|
% of the 2023 Distributions
|
Net Investment Income
|
$0.02840
|
23.12%
|
$0.02840
|
23.12%
|
Net Realized Short-Term Capital Gains
|
$0.00000
|
0.00%
|
$0.00000
|
0.00%
|
Net Realized Long-Term Capital Gains
|
$0.00000
|
0.00%
|
$0.00000
|
0.00%
|
Return of Capital (or other Capital Source)
|
$0.09445
|
76.88%
|
$0.09445
|
76.88%
|
TOTAL
|
$0.12285
|
100.00%
|
$0.12285
|
100.00%
|
Annualized Distribution Rate as a % of NAV*
|
5.42%
|
|
Cumulative Distribution Rate on NAV*
|
0.00%
|
|
Cumulative Total Return on NAV**
|
2.95%
|
|
Average Annual Total Return (in relation to NAV) for
the five-year period ended February 28, 2023***
|
5.50%
|
*
|
Based on the Fund's NAV as of February 28, 2023.
|
**
|
Cumulative fiscal year-to-date return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for
the period January 1, 2023 through February 28, 2023.
|
***
|
Average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the
last business day of the month prior to the month of the current distribution record date.
|
DISTRIBUTION ESTIMATES
|
Current Distribution | 2023 Fiscal Year * |
|
Per Share
Amount
|
% of
Current Distribution
|
Per Share
Amount
|
% of the 2023 Distributions
|
Net Investment Income
|
$0.10991
|
89.47%
|
$0.13875
|
56.47%
|
Net Realized Short-Term Capital Gains
|
$0.00132
|
1.07%
|
$0.00000
|
0.00%
|
Net Realized Long-Term Capital Gains
|
$0.01162
|
9.46%
|
$0.00680
|
2.77%
|
Return of Capital (or other Capital Source)
|
$0.00000
|
0.00%
|
$0.10015
|
40.76%
|
TOTAL
|
$0.12285
|
100.00%
|
$0.24570
|
100.00%
|
Annualized Distribution Rate as a % of NAV*
|
5.16%
|
|
Cumulative Distribution Rate on NAV*
|
1.29%
|
|
Cumulative Total Return on NAV**
|
9.66%
|
|
Average Annual Total Return (in relation to NAV) for
the five-year period ended May 31, 2023***
|
7.85%
|
*
|
Based on the Fund's NAV as of May 31, 2023.
|
**
|
Cumulative fiscal year-to-date return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for
the period January 1, 2023 through May 31, 2023.
|
***
|
Average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the
last business day of the month prior to the month of the current distribution record date.
|
DISTRIBUTION ESTIMATES
|
Current Distribution | 2023 Fiscal Year * |
Per Share
Amount
|
% of
Current
Distribution
|
Per Share
Amount
|
% of the 2023 Distributions
|
|
Net Investment Income
|
$0.00000
|
0.00%
|
$0.10028
|
27.21%
|
Net Realized Short-Term Capital Gains
|
$0.03388
|
27.58%
|
$0.04549
|
12.34%
|
Net Realized Long-Term Capital Gains
|
$0.00701
|
5.71%
|
$0.00220
|
0.60%
|
Return of Capital (or other Capital Source)
|
$0.08196
|
66.71%
|
$0.22058
|
59.85%
|
TOTAL
|
$0.12285
|
100.00%
|
$0.36855
|
100.00%
|
Annualized Distribution Rate as a % of NAV*
|
5.08%
|
|
Cumulative Distribution Rate on NAV*
|
2.54%
|
|
Cumulative Total Return on NAV**
|
12.92%
|
|
Average Annual Total Return (in relation to NAV) for
the five-year period ended August 31, 2023***
|
7.17%
|
*
|
Based on the Fund's NAV as of August 31, 2023.
|
**
|
Cumulative fiscal year-to-date return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for
the period January 1, 2023 through August 31, 2023.
|
***
|
Average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the
last business day of the month prior to the month of the current distribution record date.
|
DISTRIBUTION ESTIMATES
|
Current Distribution | 2023 Fiscal Year * |
Per Share
Amount
|
% of
Current
Distribution
|
Per Share
Amount
|
% of the 2023 Distributions
|
|
Net Investment Income
|
$0.00000
|
0.00%
|
$0.07748
|
15.57%
|
Net Realized Short-Term Capital Gains
|
$0.00000
|
0.00%
|
$0.00220
|
0.44%
|
Net Realized Long-Term Capital Gains
|
$0.10041
|
77.84%
|
$0.14590
|
29.33%
|
Return of Capital (or other Capital Source)
|
$0.02859
|
22.16%
|
$0.27197
|
54.66%
|
TOTAL
|
$0.129
|
100.00%
|
$0.49755
|
100.00%
|
Annualized Distriution Rate as a % of NAV*
|
5.33%
|
|
Cumulative Distribution Rate on NAV*
|
3.95%
|
|
Cumulative Total Return on NAV**
|
10.27%
|
|
Average Annual Total Return (in relation to NAV) for
the five-year period ended November 30, 2023***
|
7.01%
|
*
|
Based on the Fund's NAV as of November 30, 2023.
|
**
|
Cumulative fiscal year-to-date return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for
the period January 1, 2023 through November 30, 2023.
|
***
|
Average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the
last business day of the month prior to the month of the current distribution record date.
|
N-2 - $ / shares |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cover [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Entity Central Index Key | 0000813623 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amendment Flag | false | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Document Type | N-CSR | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Entity Registrant Name | Swiss Helvetia Fund, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investment Objectives and Practices [Text Block] | Investment Objective and Principal Investment Strategies
The following summarizes the Fund’s current investment objective and principal investment strategies:
Investment Objective
The Fund’s investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked
securities of non-Swiss companies in the limited instance where: (1) the Fund holds an investment in a Swiss company, and (2) such Swiss company undergoes a merger, takeover, reorganization or other form of business combination with a non-Swiss
issuer (a “reorganization”), or reorganizes (or “redomiciles”) itself as a new corporate entity outside of Switzerland, and (3) the Fund, as a stockholder in the Swiss company, acquires equity or equity-linked securities in the non-Swiss issuer as a
result of the transaction. The Fund would be permitted, but not required, to reacquire equity and equity-linked securities of Swiss companies that have redomiciled, so long as the Fund held an investment in the Swiss company at or before the time
the company redomiciled. The Fund’s investment objective is fundamental and may not be changed without the approval of a majority of the Fund’s outstanding voting securities.
Principal Investment Strategies
The Fund seeks to achieve its investment objective by normally investing at least 80% of its net assets, plus borrowings for investment purposes, in Swiss-equity and equity linked securities that are traded on a Swiss
stock exchange, traded at the pre-bourse level of one or more Swiss stock exchanges, traded through a market maker or over the counter in Switzerland. The Fund also may invest in Swiss-equity and equity-linked securities of Swiss companies that are
traded on other major European stock exchanges. Equity and equity-linked securities include registered shares, bearer shares, participation and dividend certificates, convertible bonds and bonds with warrants attached and unattached warrants.
For defensive purposes, during a period in which changes in Swiss equity markets or other adverse economic conditions or changes in Swiss political conditions warrant, the Fund may temporarily reduce its position
in equity securities and invest in Sfr-denominated bank deposits, short-term debt or money market instruments.
The Fund may invest in securities of Swiss Real Estate Companies (as defined below), and acquire, hold and sell real estate or mortgages on real estate acquired through default, liquidation or other distributions or an
interest in real estate as a result of the Fund’s ownership of such securities. Additionally, the
Fund may invest a portion of its assets in investment companies and in certain pooled investment vehicles, including those that invest in private equity by investing in private equity funds (so-called “funds of funds”) or by making direct
investments, including in infrastructure projects and real estate investments.
The Fund is permitted to (i) leverage up to 10% of its total assets (including the amount borrowed) and (ii) engage in certain options transactions. The Fund may borrow money for investment purposes and as a temporary measure for various
purposes, including the payment of dividends. The Fund may enter into options to hedge market risk and to generate income.
No assurance can be given that the Fund’s investment objective will be achieved.
Investment Philosophy and Process
In making investment decisions securities are evaluated for the opportunity for capital appreciation as well as for their potential to provide regular income and growth of income. The Adviser reviews each company’s
potential for success in light of general economic and industry trends, as well as the company’s quality of management, financial condition, business plan, industry and sector market position, dividend payout ratio and corporate governance.
Fundamental research efforts are enhanced through communication among the portfolio managers and the company’s management team, who conduct internal research and extract information from external research. The portfolio managers communicate
frequently with external analysts, and in-person visits with company management, together with local knowledge, help to provide opinions critical to investing in Swiss companies. The macroeconomic environment is reflected in fair value models. It is
also taken into account in portfolio construction, where disciplined risk diversification is applied. In addition, the Adviser incorporates financially material environmental, social and governance (ESG) factors into its investment process. The
Adviser evaluates the impact and risk around issues such as climate change, environmental performance, labor standards and corporate governance, which it views as important in its assessment of a company’s risk and potential for profitability.
Common Stocks. The Fund primarily invests in equity and equity-linked securities in the form of common stock. Common stocks represent the residual ownership interest in the
issuer and holders of common stock are entitled to the income and increase in the value of the assets and business of the issuer after all of its debt obligations and obligations to preferred stockholders are satisfied. Common stocks generally have
voting rights. Common stocks fluctuate in price in response to many factors including historical and prospective earnings of the issuer, the value of its assets, general economic conditions, interest rates, investor perceptions and market liquidity.
Convertible Securities. The Fund may invest in convertible securities, which include fixed income securities that may be exchanged or converted into a predetermined number of
shares of the issuer’s underlying common stock at the option of the holder during a specified period. Convertible securities may take the form of convertible preferred stock, convertible bonds or debentures, units consisting of bonds and warrants or
a
combination of the features of several of these securities. Investment characteristics of convertible securities vary widely, which allows these securities to be employed for a variety of investment strategies.
Investment Companies and Other Pooled Investment Vehicles. The Fund may invest in other investment companies, and may invest up to 5% of its total assets in pooled investment vehicles that invest in
private equity by investing in private equity funds (so-called “funds of funds”) or by making direct investments, including in infrastructure projects and real estate investments. The Fund is only permitted to invest in investment companies to the
extent permitted by the Investment Company Act of 1940, as amended (the “1940 Act”), and as consistent with the Fund’s investment objective and policies. Investments in private equity funds and other pooled investment vehicles are not subject to
the limitations on investing in investment companies imposed by the 1940 Act. Private equity funds are typically structured as either limited partnerships or limited liability companies
with a fixed-life, usually around ten years. The general partner of the private equity fund, who also is typically its adviser, makes investments, monitors them and finally exits them for a return on behalf of the limited partners, which are
investors such as the Fund. The private equity fund’s assets are typically invested within three to five years, and after all investments are fully divested, the private equity fund can be terminated.
Illiquid and Restricted Securities. The Fund may invest up to 10% of its total assets in illiquid securities (i.e., securities that are not readily marketable). For this
purpose, illiquid securities include, but are not limited to, restricted securities (securities the disposition of which is restricted under the Federal securities laws) and securities that may be resold pursuant to Rule 144A under the Securities
Act, but that are deemed to be illiquid. It is expected that these illiquid securities will generally consist of equity or equity-linked securities purchased in privately negotiated transactions.
Swiss Real Estate Companies. The Fund may invest in equity and equity-linked securities issued by Swiss real estate companies, including Real Estate Investment Trusts (“REITs”)
or REIT-like structures (“Swiss Real Estate Companies”). The Fund considers a real estate company to be a company that derives at least 50% of its revenue from the ownership, construction, financing, management or sale of commercial, industrial or
residential real estate or has at least 50% of its assets in real estate investments. The Fund considers a real estate company to be a Swiss Real Estate Company if it: (1) is organized in or has its principal office in Switzerland or (2) has a
significant amount of real estate assets or investments in Switzerland, even if it is organized or its principal office is outside of Switzerland. The Fund’s investment in Swiss Real Estate Companies is deemed to be an investment in Swiss equity or
equity-linked securities for purposes of the Fund’s investment objective.
Options Transactions. The Fund may engage in the following options transactions: (i) buying calls on securities in which the Fund can invest; (ii) buying calls on Swiss stock
indices; (iii) writing covered calls on securities in which the Fund can invest; (iv) buying puts on these types of securities; and (v) buying puts on Swiss stock indices. The Fund may engage in these options transactions on an established Swiss exchange, European exchange (e.g., Eurex) or through privately negotiated transactions referred to as over-the-counter options. The Adviser may utilize options
contracts to manage the Fund’s exposure to changing security prices.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk Factors [Table Text Block] | Principal Risks
The following summarizes the principal risks of an investment in the Fund:
General Risks of Investing in the Fund
Investment and Market Risk. An investment in the Fund is subject to investment risk, including the possible loss of the entire amount that you invest. Common stock prices, including the prices of shares
of the Fund’s Common Stock are sensitive to general movements in the stock market. Securities of a company may decline in value due to its financial prospects and activities, including certain operational impacts, such as data breaches and
cybersecurity attacks. Securities may also decline in value due to general market and economic movements and trends, including adverse changes to credit markets, inflation, supply chain disruptions, and labor shortages, or as a result of other
events such as geopolitical events, including, in particular, armed conflict such as is being experienced in Eastern Europe and the Middle East, natural disasters, or widespread pandemics or other adverse public health developments. As part of the
Advisers’ investment strategy, the Adviser evaluates certain factors as part of its fundamental analysis, including financially material ESG factors. The analysis of these factors may not work as intended. Market prices of the Fund’s shares of
Common Stock
may be affected by investors’ perceptions regarding closed-end funds generally or the Fund’s specific underlying investments.Market Price Discount from Net Asset Value. Shares of closed-end investment companies frequently trade at a discount from net asset value. This is a risk separate and distinct
from the risk that the Fund’s net asset value will decrease. The Fund cannot predict whether shares of its Common Stock will trade at, above or below net asset value, but the Fund’s Common Stock has generally traded at a discount.
Foreign Securities Risk. In addition to the specific risks associated with investing in Swiss securities (see, “Risk Factors—General Risks of Investing in Swiss Securities—Swiss
Securities Risk”), foreign investments generally may involve certain considerations and risks not typically associated with those of domestic origin as a result of, among other things, the possibility of political and economic developments and the
level of governmental supervision and regulation of foreign securities markets.
Equity Securities Risk. Common stock holds the lowest priority in the capital structure of a company, and therefore takes the largest share of the company’s risk and its
accompanying volatility. An adverse event, such as an unfavorable earnings report, may depress the value of a particular common stock. Also, prices of common stocks are sensitive to general market movements.
Convertible Securities Risk. Convertible securities are bonds, debentures, notes, preferred securities or other securities that may be converted or exchanged (by the holder or
the issuer) into shares of the underlying common stock (or cash or securities of equivalent value),
either at a stated price or stated rate. Convertible securities have characteristics similar to both fixed income and equity securities. Convertible securities generally are subordinated to other similar but nonconvertible securities of the same
issuer, although convertible bonds, as corporate debt obligations, enjoy seniority in right of payment to all equity securities, and convertible preferred stock is senior to common stock, of the same issuer. Illiquid and Restricted Securities Risk. The Fund may invest in restricted securities and other investments that may be illiquid. Illiquid investments involve the risk that the securities will not be able
to be sold at the time desired by the Fund or at prices approximating the value at which the Fund is carrying the securities on its books.
The Fund also may be subject to a heightened liquidity risk in respect of its investments in private equity securities, including: (i) lack of a public market; (ii) dependence on an exit strategy, such as an initial public offering or sale of a
business, which may not occur to realize the anticipated value of an investment or even dispose of the investment without a significant or total loss; and (iii) dependence on managerial assistance provided by other investors and the willingness of
other investors or third parties to provide additional financial support to the issuer.
Investing in Investment Companies and Other Pooled Investment Vehicles. The Fund’s stockholders will be subject to duplicative expenses to the extent the Fund invests in other investment companies or
pooled investment vehicles. A profit-sharing fee arrangement may create incentives for an adviser or manager to take greater investment risks in an attempt to realize a higher profit participation percentage. The securities of other investment
companies and pooled investment vehicles also may be leveraged and may, depending on the extent of leverage, be subject to greater leverage risks than to which the Fund is subject. Investment companies and pooled investment vehicles in which the
Fund may invest may have investment policies that differ from those of the Fund. In addition, the Fund will be dependent upon the investment and research abilities of persons other than the Adviser.
Investing in private equity funds presents the additional risk that the Fund may have limited access to information concerning the underlying fund and its investments. For funds that are not listed on an exchange, the
Adviser will fair value the Fund’s investment pursuant to procedures approved by the Fund’s Board of Directors. Although the Adviser will review the valuations provided by the funds, the Adviser may not be able to confirm independently the accuracy
of such valuations.
Swiss Real Estate Company Risk. In addition to the general risks associated with investing in Swiss
equity and equity-linked securities, the Fund’s investments in Swiss Real Estate Companies will be linked to the performance of the Swiss real estate markets. The Fund will not generally invest in real estate directly, and will typically invest
only in securities issued by Swiss Real Estate Companies. However, the Fund also is subject to the risks associated with the direct ownership of real estate. These risks include: (i) declines in the value of real estate; (ii) risks related to
general and local economic conditions; (iii) overbuilding and extended vacancies of properties; (iv) increases in property taxes and operating expenses; (v) costs and liabilities associated with environmental problems; and (vi) casualty or
condemnation losses. The yields available from investments in real estate depend on the amount of income and capital appreciation generated by the related properties. Property values may fall due to increasing vacancies or declining rents resulting
from unanticipated economic, legal, cultural or technological developments. Performance of investments in REITs and REIT-like structures may decline as a result of the failure of borrowers to pay their loans and poor management. Income and real
estate values also may be adversely affected by such factors as applicable laws, interest rate levels and the availability of financing. In addition, real estate investments are relatively illiquid and, therefore, the ability of real estate
companies to vary their portfolios promptly in response to changes in economic or other conditions is limited. Options Risk. The Fund is permitted, but not required, to engage in certain options transactions (relating to securities in which the Fund can invest and Swiss stock indices) which are considered
derivative instruments. The use of these options involves risks different from or possibly greater than, the risks associated with investing directly in the underlying assets. The Adviser’s may utilize options to manage the Fund’s exposure to
changing security prices. Successful use by the Fund of options will be subject to the Adviser’s ability to predict correctly movements in the prices of securities and indices underlying options and the stock market generally. To the extent the
Adviser’s predictions are incorrect, the Fund may incur losses.
Leverage Risk. Using leverage is a speculative investment technique. The use of leverage may result in higher volatility of the net asset value and the market value of the Fund’s Common Stock. Because the
interest rates on borrowings may vary, the Fund’s return will fall if interest rates rise and the Fund’s income will fluctuate. If the market value of the Fund’s portfolio declines, the leverage will result in a greater decrease in net asset value
than if the Fund were not leveraged. The Fund will pay any costs and expenses relating to any borrowings. To the extent that the Fund is required or elects to prepay any borrowings, the Fund may need to liquidate investments to fund such
prepayments. Liquidation at times of adverse economic conditions may result in capital loss and reduce returns. There can be no assurance that any leverage strategy the Fund employs will be successful.
General Risks of Investing in Swiss Securities
Swiss Securities Risk. Trading in Swiss equities involves certain risks and special considerations not usually associated with investing in securities of established U.S.
companies, including (i) risks related to the nature of the market for Swiss equities, including the risk that the Swiss equities markets may be affected
by market developments in different ways than U.S. securities markets and may be more volatile than U.S. securities markets; (ii) political and economic risks with respect to Switzerland, including the possible imposition of, or changes in,
currency exchange laws or other Swiss laws or restrictions applicable to investments in Swiss equities; and (iii) fluctuations in the rate of exchange between currencies and costs associated with currency conversion. Swiss Market and Concentration Risk. The Swiss securities markets have substantially less trading volume than the U.S. securities markets. Additionally, the capitalization of the Swiss securities markets
is highly concentrated. As of December 31, 2023, the top three holdings in the main overall performance index in Switzerland, the Swiss Performance Index, accounted for 42% of the index. By comparison, as of the same date, the Fund has three
holdings that exceed 5% of its net assets which, in the aggregate, constitute 39.4% of its net assets. Securities of some companies located in Switzerland will be less liquid and more volatile than securities of comparable U.S. companies. This
combination of lower volume and greater concentration in the Swiss securities markets may create a risk of greater price volatility than in the U.S. securities markets. Commissions for trading on Swiss exchanges are generally higher than
commissions for trading on U.S. exchanges, although the Adviser seeks the most favorable net results (taking into account transaction costs) on the Fund’s portfolio transactions and, in certain instances, may be able to purchase portfolio
investments on which commissions are negotiable. Further, Swiss markets typically have less government supervision compared to the U.S. markets.
Disclosure Standards Risk. Swiss reporting, accounting and auditing standards differ from U.S. standards in important respects. Swiss corporations, other than subsidiaries of U.S. companies, do not
provide all of the disclosure required by U.S. law and accounting practice, and such disclosure may be less timely than required of U.S. companies by the Securities and Exchange Commission (the “SEC”) or under U.S. generally accepted accounting
principles (“U.S. GAAP”). As a result, less specific information may be available to investors in Swiss securities than to investors in U.S. securities. Swiss banks and insurance companies are subject to stricter disclosure requirements than other
Swiss companies, but these rules are not as comprehensive as SEC or U.S. GAAP reporting standards.
Foreign Currency and Exchange Rate Risk. Substantially all of the Fund’s assets are invested in Swiss equities and equity-linked securities. In addition, the Fund makes its temporary investments in Swiss
franc-denominated bank deposits, short-term debt securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund’s net asset value, however, is reported, and distributions from the Fund are made,
in U.S. dollars. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. Accordingly, currency risks in connection with investments in the Fund will be borne by
investors. Therefore, the Fund’s reported net asset value and distributions could be adversely affected by devaluation of the Swiss franc relative to the U.S. dollar. In addition, the Fund computes its income at the foreign
exchange rate in effect on the day of its receipt by the Fund. If the value of the Swiss franc falls relative to the U.S. dollar between the date the Fund receives such income and the date it makes distributions, and, if the Fund has
insufficient cash in U.S. dollars to meet distribution requirements, it may be required to liquidate securities in order to make distributions. There is no assurance that the Fund will be able to liquidate securities in order to meet such
distribution requirements. Such liquidations, if required, also may adversely affect the Fund.
Tax Risk. Dividends and certain interest paid to the Fund by Swiss corporate entities will be subject to certain withholding taxes in Switzerland. Subject to certain limitations imposed by the Internal
Revenue Code of 1986, as amended (the “Code”), foreign taxes withheld from distributions to the Fund or otherwise paid by the Fund may be creditable against taxes owed or deductible from income by U.S. stockholders for U.S. Federal income tax
purposes if the Fund makes an election to treat the stockholders as having paid those taxes for U.S. Federal income tax purposes. The Fund’s ability to make such an election is subject to certain requirements in the Code. Although the Fund expects
to be eligible to make such an election each year, and intends to do so if it is eligible, there is no assurance that the Fund will be eligible each year. If the election is made, the amount of such foreign taxes paid by the Fund will be includible
as income to the stockholders for U.S. Federal income tax purposes. Non-U.S. investors may not be able to credit or deduct such foreign taxes, but may be deemed to have additional income from the Fund subject to U.S. withholding tax. Investors
should review carefully the information discussed under “U.S. Federal Taxation” below and should discuss with their tax advisors the specific tax consequences of investing in the Fund.
Additional Risk Considerations
Cybersecurity Risk. With the increased use of technologies by Fund service providers to conduct business, such as the Internet, the Fund is susceptible to operational, information security and related
risks. In general, cyber incidents can result from deliberate attacks or unintentional events. Cybersecurity failures by or breaches of the Adviser or the Fund’s administrator and other service providers (including, but not limited to, the
custodian or transfer agent), and the issuers of securities in which the Fund invests, may disrupt and otherwise adversely affect their business operations. This may result in financial losses to the Fund, impede Fund trading, interfere with the
Fund’s ability to calculate its NAV, interfere with Fund stockholders’ ability to transact business or cause violations of applicable privacy and other laws, regulatory fines, penalties, reputational damage, reimbursement or other compensation
costs, or additional compliance costs.
Non-Diversified Status. The Fund is classified as “non-diversified” under the 1940 Act. A non-diversified fund has the ability to invest more of its assets in securities of a single issuer than if it were
classified as a “diversified” fund, which may increase volatility. If the Fund’s investment in an issuer represents a relatively significant percentage of the Fund’s portfolio, the value of the Fund’s portfolio will be more impacted by a loss on
that investment than if the portfolio were more diversified.
Risk of Anti-Takeover Provisions. The Fund has provisions in its Articles of Incorporation and By-laws that could have the effect of delaying, deferring, preventing or otherwise limiting the ability of
other entities or persons to acquire control of the Fund, to cause the Fund to engage in certain transactions or to modify the Fund’s structure.
General Fund Investing Risks. The Fund is not a complete investment program and there is no guarantee that the Fund will achieve its investment objective. It is possible to
lose money by investing in the Fund. An investment in the Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock [Table Text Block] | Note 4—Capital Share Transactions
The Fund is authorized to issue up to 50 million shares of capital stock. Transactions in capital shares were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Document Period End Date | Dec. 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investment and Market Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Investment and Market Risk. An investment in the Fund is subject to investment risk, including the possible loss of the entire amount that you invest. Common stock prices, including the prices of shares
of the Fund’s Common Stock are sensitive to general movements in the stock market. Securities of a company may decline in value due to its financial prospects and activities, including certain operational impacts, such as data breaches and
cybersecurity attacks. Securities may also decline in value due to general market and economic movements and trends, including adverse changes to credit markets, inflation, supply chain disruptions, and labor shortages, or as a result of other
events such as geopolitical events, including, in particular, armed conflict such as is being experienced in Eastern Europe and the Middle East, natural disasters, or widespread pandemics or other adverse public health developments. As part of the
Advisers’ investment strategy, the Adviser evaluates certain factors as part of its fundamental analysis, including financially material ESG factors. The analysis of these factors may not work as intended. Market prices of the Fund’s shares of
Common Stock
may be affected by investors’ perceptions regarding closed-end funds generally or the Fund’s specific underlying investments. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Price Discount from Net Asset Value [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Market Price Discount from Net Asset Value. Shares of closed-end investment companies frequently trade at a discount from net asset value. This is a risk separate and distinct
from the risk that the Fund’s net asset value will decrease. The Fund cannot predict whether shares of its Common Stock will trade at, above or below net asset value, but the Fund’s Common Stock has generally traded at a discount.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign Securities Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Foreign Securities Risk. In addition to the specific risks associated with investing in Swiss securities (see, “Risk Factors—General Risks of Investing in Swiss Securities—Swiss
Securities Risk”), foreign investments generally may involve certain considerations and risks not typically associated with those of domestic origin as a result of, among other things, the possibility of political and economic developments and the
level of governmental supervision and regulation of foreign securities markets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Securities Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Equity Securities Risk. Common stock holds the lowest priority in the capital structure of a company, and therefore takes the largest share of the company’s risk and its
accompanying volatility. An adverse event, such as an unfavorable earnings report, may depress the value of a particular common stock. Also, prices of common stocks are sensitive to general market movements.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Securities Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Convertible Securities Risk. Convertible securities are bonds, debentures, notes, preferred securities or other securities that may be converted or exchanged (by the holder or
the issuer) into shares of the underlying common stock (or cash or securities of equivalent value),
either at a stated price or stated rate. Convertible securities have characteristics similar to both fixed income and equity securities. Convertible securities generally are subordinated to other similar but nonconvertible securities of the same
issuer, although convertible bonds, as corporate debt obligations, enjoy seniority in right of payment to all equity securities, and convertible preferred stock is senior to common stock, of the same issuer.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illiquid and Restricted Securities Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Illiquid and Restricted Securities Risk. The Fund may invest in restricted securities and other investments that may be illiquid. Illiquid investments involve the risk that the securities will not be able
to be sold at the time desired by the Fund or at prices approximating the value at which the Fund is carrying the securities on its books.
The Fund also may be subject to a heightened liquidity risk in respect of its investments in private equity securities, including: (i) lack of a public market; (ii) dependence on an exit strategy, such as an initial public offering or sale of a
business, which may not occur to realize the anticipated value of an investment or even dispose of the investment without a significant or total loss; and (iii) dependence on managerial assistance provided by other investors and the willingness of
other investors or third parties to provide additional financial support to the issuer.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investing in Investment Companies and Other Pooled Investment Vehicles [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Investing in Investment Companies and Other Pooled Investment Vehicles. The Fund’s stockholders will be subject to duplicative expenses to the extent the Fund invests in other investment companies or
pooled investment vehicles. A profit-sharing fee arrangement may create incentives for an adviser or manager to take greater investment risks in an attempt to realize a higher profit participation percentage. The securities of other investment
companies and pooled investment vehicles also may be leveraged and may, depending on the extent of leverage, be subject to greater leverage risks than to which the Fund is subject. Investment companies and pooled investment vehicles in which the
Fund may invest may have investment policies that differ from those of the Fund. In addition, the Fund will be dependent upon the investment and research abilities of persons other than the Adviser.
Investing in private equity funds presents the additional risk that the Fund may have limited access to information concerning the underlying fund and its investments. For funds that are not listed on an exchange, the
Adviser will fair value the Fund’s investment pursuant to procedures approved by the Fund’s Board of Directors. Although the Adviser will review the valuations provided by the funds, the Adviser may not be able to confirm independently the accuracy
of such valuations.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Swiss Real Estate Company Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Swiss Real Estate Company Risk. In addition to the general risks associated with investing in Swiss
equity and equity-linked securities, the Fund’s investments in Swiss Real Estate Companies will be linked to the performance of the Swiss real estate markets. The Fund will not generally invest in real estate directly, and will typically invest
only in securities issued by Swiss Real Estate Companies. However, the Fund also is subject to the risks associated with the direct ownership of real estate. These risks include: (i) declines in the value of real estate; (ii) risks related to
general and local economic conditions; (iii) overbuilding and extended vacancies of properties; (iv) increases in property taxes and operating expenses; (v) costs and liabilities associated with environmental problems; and (vi) casualty or
condemnation losses. The yields available from investments in real estate depend on the amount of income and capital appreciation generated by the related properties. Property values may fall due to increasing vacancies or declining rents resulting
from unanticipated economic, legal, cultural or technological developments. Performance of investments in REITs and REIT-like structures may decline as a result of the failure of borrowers to pay their loans and poor management. Income and real
estate values also may be adversely affected by such factors as applicable laws, interest rate levels and the availability of financing. In addition, real estate investments are relatively illiquid and, therefore, the ability of real estate
companies to vary their portfolios promptly in response to changes in economic or other conditions is limited.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Options Risk. The Fund is permitted, but not required, to engage in certain options transactions (relating to securities in which the Fund can invest and Swiss stock indices) which are considered
derivative instruments. The use of these options involves risks different from or possibly greater than, the risks associated with investing directly in the underlying assets. The Adviser’s may utilize options to manage the Fund’s exposure to
changing security prices. Successful use by the Fund of options will be subject to the Adviser’s ability to predict correctly movements in the prices of securities and indices underlying options and the stock market generally. To the extent the
Adviser’s predictions are incorrect, the Fund may incur losses.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leverage Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Leverage Risk. Using leverage is a speculative investment technique. The use of leverage may result in higher volatility of the net asset value and the market value of the Fund’s Common Stock. Because the
interest rates on borrowings may vary, the Fund’s return will fall if interest rates rise and the Fund’s income will fluctuate. If the market value of the Fund’s portfolio declines, the leverage will result in a greater decrease in net asset value
than if the Fund were not leveraged. The Fund will pay any costs and expenses relating to any borrowings. To the extent that the Fund is required or elects to prepay any borrowings, the Fund may need to liquidate investments to fund such
prepayments. Liquidation at times of adverse economic conditions may result in capital loss and reduce returns. There can be no assurance that any leverage strategy the Fund employs will be successful.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Swiss Securities Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Swiss Securities Risk. Trading in Swiss equities involves certain risks and special considerations not usually associated with investing in securities of established U.S.
companies, including (i) risks related to the nature of the market for Swiss equities, including the risk that the Swiss equities markets may be affected
by market developments in different ways than U.S. securities markets and may be more volatile than U.S. securities markets; (ii) political and economic risks with respect to Switzerland, including the possible imposition of, or changes in,
currency exchange laws or other Swiss laws or restrictions applicable to investments in Swiss equities; and (iii) fluctuations in the rate of exchange between currencies and costs associated with currency conversion.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Swiss Market and Concentration Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Swiss Market and Concentration Risk. The Swiss securities markets have substantially less trading volume than the U.S. securities markets. Additionally, the capitalization of the Swiss securities markets
is highly concentrated. As of December 31, 2023, the top three holdings in the main overall performance index in Switzerland, the Swiss Performance Index, accounted for 42% of the index. By comparison, as of the same date, the Fund has three
holdings that exceed 5% of its net assets which, in the aggregate, constitute 39.4% of its net assets. Securities of some companies located in Switzerland will be less liquid and more volatile than securities of comparable U.S. companies. This
combination of lower volume and greater concentration in the Swiss securities markets may create a risk of greater price volatility than in the U.S. securities markets. Commissions for trading on Swiss exchanges are generally higher than
commissions for trading on U.S. exchanges, although the Adviser seeks the most favorable net results (taking into account transaction costs) on the Fund’s portfolio transactions and, in certain instances, may be able to purchase portfolio
investments on which commissions are negotiable. Further, Swiss markets typically have less government supervision compared to the U.S. markets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure Standards Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Disclosure Standards Risk. Swiss reporting, accounting and auditing standards differ from U.S. standards in important respects. Swiss corporations, other than subsidiaries of U.S. companies, do not
provide all of the disclosure required by U.S. law and accounting practice, and such disclosure may be less timely than required of U.S. companies by the Securities and Exchange Commission (the “SEC”) or under U.S. generally accepted accounting
principles (“U.S. GAAP”). As a result, less specific information may be available to investors in Swiss securities than to investors in U.S. securities. Swiss banks and insurance companies are subject to stricter disclosure requirements than other
Swiss companies, but these rules are not as comprehensive as SEC or U.S. GAAP reporting standards.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign Currency and Exchange Rate Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Foreign Currency and Exchange Rate Risk. Substantially all of the Fund’s assets are invested in Swiss equities and equity-linked securities. In addition, the Fund makes its temporary investments in Swiss
franc-denominated bank deposits, short-term debt securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund’s net asset value, however, is reported, and distributions from the Fund are made,
in U.S. dollars. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. Accordingly, currency risks in connection with investments in the Fund will be borne by
investors. Therefore, the Fund’s reported net asset value and distributions could be adversely affected by devaluation of the Swiss franc relative to the U.S. dollar. In addition, the Fund computes its income at the foreign
exchange rate in effect on the day of its receipt by the Fund. If the value of the Swiss franc falls relative to the U.S. dollar between the date the Fund receives such income and the date it makes distributions, and, if the Fund has
insufficient cash in U.S. dollars to meet distribution requirements, it may be required to liquidate securities in order to make distributions. There is no assurance that the Fund will be able to liquidate securities in order to meet such
distribution requirements. Such liquidations, if required, also may adversely affect the Fund.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tax Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Tax Risk. Dividends and certain interest paid to the Fund by Swiss corporate entities will be subject to certain withholding taxes in Switzerland. Subject to certain limitations imposed by the Internal
Revenue Code of 1986, as amended (the “Code”), foreign taxes withheld from distributions to the Fund or otherwise paid by the Fund may be creditable against taxes owed or deductible from income by U.S. stockholders for U.S. Federal income tax
purposes if the Fund makes an election to treat the stockholders as having paid those taxes for U.S. Federal income tax purposes. The Fund’s ability to make such an election is subject to certain requirements in the Code. Although the Fund expects
to be eligible to make such an election each year, and intends to do so if it is eligible, there is no assurance that the Fund will be eligible each year. If the election is made, the amount of such foreign taxes paid by the Fund will be includible
as income to the stockholders for U.S. Federal income tax purposes. Non-U.S. investors may not be able to credit or deduct such foreign taxes, but may be deemed to have additional income from the Fund subject to U.S. withholding tax. Investors
should review carefully the information discussed under “U.S. Federal Taxation” below and should discuss with their tax advisors the specific tax consequences of investing in the Fund.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cybersecurity Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Cybersecurity Risk. With the increased use of technologies by Fund service providers to conduct business, such as the Internet, the Fund is susceptible to operational, information security and related
risks. In general, cyber incidents can result from deliberate attacks or unintentional events. Cybersecurity failures by or breaches of the Adviser or the Fund’s administrator and other service providers (including, but not limited to, the
custodian or transfer agent), and the issuers of securities in which the Fund invests, may disrupt and otherwise adversely affect their business operations. This may result in financial losses to the Fund, impede Fund trading, interfere with the
Fund’s ability to calculate its NAV, interfere with Fund stockholders’ ability to transact business or cause violations of applicable privacy and other laws, regulatory fines, penalties, reputational damage, reimbursement or other compensation
costs, or additional compliance costs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-Diversified Status [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Non-Diversified Status. The Fund is classified as “non-diversified” under the 1940 Act. A non-diversified fund has the ability to invest more of its assets in securities of a single issuer than if it were
classified as a “diversified” fund, which may increase volatility. If the Fund’s investment in an issuer represents a relatively significant percentage of the Fund’s portfolio, the value of the Fund’s portfolio will be more impacted by a loss on
that investment than if the portfolio were more diversified.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk of Anti-Takeover Provisions [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | Risk of Anti-Takeover Provisions. The Fund has provisions in its Articles of Incorporation and By-laws that could have the effect of delaying, deferring, preventing or otherwise limiting the ability of
other entities or persons to acquire control of the Fund, to cause the Fund to engage in certain transactions or to modify the Fund’s structure.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Fund Investing Risks [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk [Text Block] | General Fund Investing Risks. The Fund is not a complete investment program and there is no guarantee that the Fund will achieve its investment objective. It is possible to
lose money by investing in the Fund. An investment in the Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Shares [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ 8.20 | $ 8.20 | $ 7.56 | $ 9.94 | $ 8.94 | $ 8.41 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAV Per Share | $ 9.76 | $ 9.76 | $ 8.80 | $ 11.50 | $ 10.45 | $ 9.71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding Security, Authorized [Shares] | 50,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding Security, Not Held [Shares] | 12,990,705 |
1 Year Swiss Helvetia Chart |
1 Month Swiss Helvetia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions